{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:37:30Z","timestamp":1761561450437},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T00:00:00Z","timestamp":1181952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:sec><jats:title>Summary<\/jats:title><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Early identification of true responders to acid suppression in functional dyspepsia patients with symptoms of epigastric pain or burning may enable clinicians to optimally tailor treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate whether a 1\u2010w acid suppression trial is useful for identifying true responders in this population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients (18\u201370\u2003years) were randomized to either esomeprazole 40\u2003mg q.d.s., b.d. or placebo for 1w, and then esomeprazole 40\u2003mg q.d.s. or placebo for 7w. Epigastric pain and\/or burning were recorded on a 4\u2010point scale (0\u2003=\u2003none, 3\u2003=\u2003severe). Trial\u2010week response was defined as symptom score sum \u22641 on last 3d of therapy; response at 8w was symptom score sum \u22641 over preceding 7d.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>1\u2010w response rates were 33% (199 of 597), 29% (188 of 629) and 23% (71 of 315) with esomeprazole q.d.s., esomeprazole b.d. and placebo, respectively (<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.002 for esomeprazole groups vs. placebo). At 8w, trial week sensitivity and specificity were 46% and 80%, respectively, for esomeprazole (40 or 80\u2003mg), and 33% and 87%, respectively, for placebo. The positive and negative predictive values for esomeprazole were 60% and 69%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Response to a 1\u2010w acid suppression trial is of limited use for predicting symptom response at 8w in patients with unexplained epigastric pain or burning.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2007.03410.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T12:03:40Z","timestamp":1279886620000},"page":"673-682","source":"Crossref","is-referenced-by-count":36,"title":["Randomized\u2010controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1\u2010week trial of acid suppression predict symptom response?"],"prefix":"10.1111","volume":"26","author":[{"given":"N. J","family":"TALLEY","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"VAKIL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"LAURITSEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. V.","family":"VAN ZANTEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"FLOOK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"BOLLING\u2010STERNEVALD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"PERSSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"BJ\u00d6RCK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"LIND","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"ON BEHALF OF THE STARS I STUDY GROUP","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,6,16]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.09.020"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01706.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-102-2-266"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.08.026"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00410.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6943.1552"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.00225.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.059"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-9_Part_2-200105011-00004"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.1566"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2008.ii69"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02845.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-7-200404060-00011"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.41657.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.01.008"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00630.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.suppl_4.iv2"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.042143"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03410.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03410.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T22:01:54Z","timestamp":1697234514000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03410.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,16]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03410.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03410.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"type":"print","value":"0269-2813"},{"type":"electronic","value":"1365-2036"}],"subject":[],"published":{"date-parts":[[2007,6,16]]}}}